Discover

Back to filter

Related topics

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles

Spectral Instruments Imaging

Jun 23, 2021

Overactivation of the PI3K/mTOR signaling has been identified in non-Hodgkin’s lymphoma....

Top 10 Pharma companies have chosen CYTEK for their flow cytometry facility

Cytek Biosciences

Jun 21, 2021

6 of Top 10 Pharma Companies (Based on total group revenues) have chosen CYTEK - full...

Elevated NSD3 histone methylation activity drives squamous cell lung cancer

Spectral Instruments Imaging

Jun 8, 2021

This work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in...

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic

Tonbo Biosciences

May 21, 2021

Tonbo Biosciences flow cytometry reagents & antibodies are manufactured with the highest...

IncuCyte webinar recording: How to measure Immune Cell Killing of Tumor Cells effectively

Sartorius

May 19, 2021

Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO...

White Paper: Immunophenotyping Rare Immune Cells with Laminar Wash AUTO System

Curiox

May 18, 2021

The Laminar Wash (LW) AUTO system consists of a wall-less plate and a laminar flow cell...

Show all topics (10)

Preclinical imaging for drug discovery and development

Dec 12, 2016

Advances in multimodal preclinical imaging enable tracking of physiologic and structural changes together in vivo, for highly efficient longitudinal studies of disease progress and drug distribution, delivery and therapeutic response. Same-session X-ray, PET, SPECT, and/or optical views - automatically co-registered - provide detailed anatomic context for physiological metrics such as candidate biomarkers. Advanced software and techniques like spectral unmixing enable tracking of multiple measures together - for example, quantifying critical gene and protein expression, or co-locating a drug compound and its target.

Bruker's modular multimodal imaging systems let you choose which modalities to use with the option to add modalities as needed later, all within the same, small footprint. For highly detailed anatomic and functional studies, Bruker MRI and magnetic particle imaging systems provide outstanding spatial and time resolution, and complement clinical imaging methods for rapid translation of study results between animals and patients.

Learn more about preclinical imaging methods for drug discovery and development.

Read more

 

Scientific paper
Application

Brand profile

Bruker Biospin

Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.

Related products

Albira combines PET, SPECT and CT imaging in a unique and extremely powerful way

show detail

MRI and PET imaging combined for the best of both worlds

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey